Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
May 14 2019 - 4:15PM
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a
late-stage clinical biopharmaceutical company, today announced that
Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep
Division, Professor of Medicine at Tufts University School of
Medicine, and INSPIRE Principal Investigator, will
present a poster highlighting data from Liquidia’s Phase 3 INSPIRE
trial of LIQ861 for the treatment of pulmonary arterial
hypertension (PAH) at the ATS International Conference in Dallas,
Texas. The poster will include data on tolerability of LIQ861 and
selected exploratory endpoints at two months of treatment, split by
New York Heart Association Functional Class.
|
|
|
Presentation details
are as follows: |
|
|
|
Title: |
|
INSPIRE: A Phase 3 Open-Label,
Multicenter Study to Evaluate the Safety and Tolerability of LIQ861
in Pulmonary Arterial Hypertension (PAH) |
|
|
|
Poster Board Number: |
|
P1155 |
|
|
|
Date/Time: |
|
Tuesday, May 21; 11:15 a.m. – 1
p.m. CT |
|
|
|
Location: |
|
Area J (Hall F, Level 2),
KBHCCD |
|
|
|
A copy of the
poster will be available on the company’s website
following the presentation. |
|
|
|
About LIQ861
Liquidia has developed LIQ861, a dry powder
formulation of treprostinil utilizing PRINT® Technology, which is
specifically designed to enhance deep-lung delivery and enables QID
delivery of treprostinil doses in 1 to 2 breaths per capsule via a
convenient, palm-sized dry powder inhaler (DPI). PRINT® Technology
results in a treprostinil drug product with particles of a precise,
uniform size, shape and composition that are engineered for optimal
deposition in the lung following oral inhalation using a DPI.
LIQ861 may enhance lung delivery and pharmacodynamic effects of
treprostinil in patients diagnosed with PAH.
About INSPIRE Clinical Trial
Liquidia’s pivotal open-label Phase 3 clinical
trial, known as INSPIRE, or Investigation of the Safety and
Pharmacology of Dry Powder Inhalation of Treprostinil, is
designed to evaluate patients who have either been under stable
treatment with nebulizer-delivered treprostinil for at least three
months and are transitioned to LIQ861 under the protocol
(Transition) or patients who have been on stable treatment with no
more than two non-prostacyclin oral PAH therapies for at least
three months and have their treatment regimen supplemented with
LIQ861 under the protocol (Add-on). The primary objective of the
INSPIRE study is to evaluate the long-term safety and tolerability
of LIQ861. INSPIRE also includes exploratory endpoints to assess
clinical benefits such as 6 Minute Walk Distance (6MWD) and quality
of life. For more information, please
visit https://clinicaltrials.gov/ct2/show/NCT03399604.
About Liquidia Technologies
Liquidia is a late-stage clinical biopharmaceutical
company focused on the development and commercialization of
therapeutics using its proprietary PRINT® technology to transform
the lives of patients. Currently, Liquidia is focused on the
development of two product candidates using its PRINT® particle
engineering platform: LIQ861 for the treatment of pulmonary
arterial hypertension and LIQ865 for the treatment of local
post-operative pain. Being evaluated in a Phase 3 clinical trial
(INSPIRE), LIQ861 is designed to improve the therapeutic profile of
treprostinil by enhancing deep-lung delivery and achieving higher
dose levels than current inhaled therapies by using a convenient,
palm-sized, disposable dry powder inhaler. LIQ865, for which
Liquidia has completed two Phase 1 clinical trials, is designed to
deliver sustained-release particles of bupivacaine, a non-opioid
anesthetic, to treat local post-operative pain for three to five
days through a single administration. For more information visit
Liquidia’s website at www.liquidia.com.
Forward-Looking Statements
This press release may include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
other than statements of historical facts, including statements
regarding our future results of operations and financial position,
our business strategy and plans and our objectives for future
operations, are forward-looking statements. Such forward-looking
statements, including statements regarding clinical trials,
clinical studies and other clinical work (including the funding
therefor, anticipated patient enrollment, safety data, study data,
trial outcomes, timing or associated costs), regulatory
applications and related timelines, including the filing of an NDA
for LIQ861, involve significant risks and uncertainties and actual
results could differ materially from those expressed or implied
herein. The words “anticipate,” “believe,” “continue,” “estimate,”
“expect,” “intend,” “may,” “will” and similar expressions are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives and financial needs. These
forward-looking statements are subject to a number of risks
discussed in our filings with the Securities and Exchange
Commission, as well as a number of uncertainties and assumptions.
Moreover, we operate in a very competitive and rapidly changing
environment and our industry has inherent risks. New risks emerge
from time to time. It is not possible for our management to predict
all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make. In light
of these risks, uncertainties and assumptions, the future events
discussed in this press release may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. Nothing in this press
release should be regarded as a representation by any person that
these goals will be achieved, and we undertake no duty to update
our goals or to update or alter any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact
InformationInvestors:Jenny KobinIR
Advisory Solutions919.328.4389IR@liquidia.com
Media:Christy CurranSam Brown
Inc.615.414.8668media@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Sep 2023 to Sep 2024